Evidence map›Paper›PMID 30911587›Full record

ArticleMolecular therapy. Methods & clinical development2019

Safety of CD34

Marianne Delville, Fabien Touzot, Chloé Couzin, Isabelle Hmitou, Lounes Djerroudi, Amani Ouedrani, François Lefrère, Caroline Tuchman-Durand, Chloé Mollet, Jean-Roch Fabreguettes and 18 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Methods & clinical development, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.4field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors at 8 institutions in 2 countries.

Marianne DelvilleParis Descartes, Sorbonne Paris Cité, France.
Fabien TouzotParis Descartes, Sorbonne Paris Cité, France.
Chloé CouzinParis Descartes, Sorbonne Paris Cité, France.
Isabelle HmitouClinical Investigation Center CIC1416 and Département de Biothérapie, Hôpital Necker, Assistance Publique des Hôpitaux de Paris, Paris, France.
Lounes DjerroudiClinical Investigation Center CIC1416 and Département de Biothérapie, Hôpital Necker, Assistance Publique des Hôpitaux de Paris, Paris, France.
Amani OuedraniClinical Investigation Center CIC1416 and Département de Biothérapie, Hôpital Necker, Assistance Publique des Hôpitaux de Paris, Paris, France.
François LefrèreClinical Investigation Center CIC1416 and Département de Biothérapie, Hôpital Necker, Assistance Publique des Hôpitaux de Paris, Paris, France.
Caroline Tuchman-DurandClinical Investigation Center CIC1416 and Département de Biothérapie, Hôpital Necker, Assistance Publique des Hôpitaux de Paris, Paris, France.
Chloé MolletClinical Investigation Center CIC1416 and Département de Biothérapie, Hôpital Necker, Assistance Publique des Hôpitaux de Paris, Paris, France.
Jean-Roch FabreguettesDépartement Essais Cliniques, AGEPS, Assistance Publique des Hôpitaux de Paris, Paris, France.
Nicolas FerryHôpital Saint Louis, Assistance Publique des Hôpitaux de Paris, Paris, France.
Laurent LaganierClinical Investigation Center CIC1416 and Département de Biothérapie, Hôpital Necker, Assistance Publique des Hôpitaux de Paris, Paris, France.
Alessandra MagnaniClinical Investigation Center CIC1416 and Département de Biothérapie, Hôpital Necker, Assistance Publique des Hôpitaux de Paris, Paris, France.
Elisa MagrinClinical Investigation Center CIC1416 and Département de Biothérapie, Hôpital Necker, Assistance Publique des Hôpitaux de Paris, Paris, France.
Valérie JolaineParis Descartes Necker - Cochin Clinical Research Unit, Assistance Publique-Hôpitaux de Paris, Paris, France.
Asier Saez-CirionUnité HIV Inflammation et Persistance, Institut Pasteur, Paris, France.
Orit WolsteinCSL Behring, LLC (formerly Calimmune, Inc.), Darlinghurst, NSW, Australia.
Geoffrey SymondsCSL Behring, LLC (formerly Calimmune, Inc.), Darlinghurst, NSW, Australia.
Pierre FrangeEHU 7328, Institut Imagine, Université Paris Descartes, Sorbonne Paris Cité, France.
Hélène Moins-TeisserencINSERM U1160, Université Paris Diderot and Département d'Immunologie, Hôpital Saint Louis, Assistance Publique des Hôpitaux de Paris, Paris, France.
Marie-Laure Chaix-BaudierINSERM U944, Université Paris Diderot and Laboratoire de Virology Hôpital Saint-Louis, Paris, France.
Antoine ToubertINSERM U1160, Université Paris Diderot and Département d'Immunologie, Hôpital Saint Louis, Assistance Publique des Hôpitaux de Paris, Paris, France.
Jérôme LargheroCIC de Biothérapie CBT501, Université Paris Diderot and Hôpital Saint Louis, Assistance Publique des Hôpitaux de Paris, Paris, France.
Nathalie ParquetDépartement d'Aphérèse Thérapeutique, Hôpital Saint Louis, Assistance Publique des Hôpitaux de Paris, Paris, France.
Anne C BrignierDépartement d'Aphérèse Thérapeutique, Hôpital Saint Louis, Assistance Publique des Hôpitaux de Paris, Paris, France.
Françoise Barré-SinoussiDépartement des Affaires Internationales, Institut Pasteur, Paris, France.
Eric OksenhendlerUniversité Paris Diderot and Service d'Immunopathologie Clinique, Hôpital Saint Louis, Assistance Publique des Hôpitaux de Paris, Paris, France.
Marina CavazzanaParis Descartes, Sorbonne Paris Cité, France.
Hôpital Necker-Enfants Malades · FRHôpital Saint-Louis · FRUniversité Paris Cité · FRCSL (Australia) · AUDélégation Paris 5 · FRInstitut Pasteur · FRAssistance Publique – Hôpitaux de Paris · FRDélégation Paris 7 · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although the risk of developing lymphoma has decreased in the highly active antiretroviral therapy era, this cancer remains the major cause of mortality in HIV-infected patients. Autologous hematopoietic stem cell transplantation (ASCT) outcome does not differ for HIV-infected versus HIV-uninfected patients. We propose to develop a new treatment for HIV-associated high-risk lymphoma based on autologous transplantation of two genetically modified products: CD4

Identifiers

PMID30911587
PMCPMC6416524
OpenAlexW2916357538

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.